The “difficult decision” was made “in order to protect other vital NHS services”, the National Institute for Health and Care ...

Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), ...

Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...

After this, the situation will be reviewed by Nice, who will provide further guidance on the rollout. Mounjaro is a ...

While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Other work primarily only included glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among individuals with substance use disorders. We also compared GLP-1 RAs to metformin and ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

While surgery has a low risk for complications, when they do occur, they are serious. This may explain why only 5%-10% of ...

A study finds that anti-obesity medications may help reduce alcohol consumption, with nearly half of participants in weight ...

Eli Lilly's Zepbound outperformed Wegovy in weight loss and key outcomes during the SURMOUNT-5 trial, showing a comparable ...

Amylyx (AMLX) announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class ...